• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用(1-38)人甲状旁腺激素(hPTH)和双膦酸盐依替膦酸二钠(EHDP)对骨质疏松症低骨代谢进行刺激疗法的结果。研究I方案,汉诺威骨质疏松症试验

Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study I, osteoporosis trial Hannover.

作者信息

Hesch R D, Heck J, Delling G, Keck E, Reeve J, Canzler H, Schober O, Harms H, Rittinghaus E F

机构信息

Abteilung für Klinische Endokrinologie Diätetik und Nuklearmedizin, Medizinischen Hochschule Hannover.

出版信息

Klin Wochenschr. 1988 Oct 3;66(19):976-84. doi: 10.1007/BF01738113.

DOI:10.1007/BF01738113
PMID:3141672
Abstract

In contrast to prevention, the therapy of manifest osteoporosis remains a clinically significant problem. So far all therapeutic attempts have yielded unsatisfying results. For this reason we have tried to achieve a positive bone balance by sequential stimulation and inhibition of the osseous metabolism. The therapy consisted of six 14-day courses with 400 units (1-38)hPTH per day and, in addition, starting with the 2nd week of PTH therapy, EHDP 5 mg per kg body weight per day for a total of 2 weeks. Already the initial therapeutic course resulted in a stimulation of decreased bone metabolism which could be documented by an increase in the calcium-47 accretion rate (six patients). An increase of the alkaline phosphatase could be noted (four patients); this, however, did not correlate with the calcium accretion. A positive calcium balance could, nonetheless, only be attained in four of eight patients within this period, while neither the alkaline phosphatase nor the kinetics would allow a prediction of this effect. Changes of the balance coincided with equal changes in the net calcium absorption. The urinary calcium excretion increased temporarily during the therapeutic phase. We were not able to detect an influence on the vitamin D metabolites. Histomorphometric studies did not demonstrate an increase in bone mass in the iliac creast after six therapeutic courses. Nevertheless, progressive deformations of vertebral bodies did not occur. We conclude that already after 2 weeks this therapeutic concept can lead to a stimulation of bone metabolism.

摘要

与预防不同,显性骨质疏松症的治疗仍然是一个具有临床重要性的问题。到目前为止,所有的治疗尝试都取得了不尽人意的结果。因此,我们试图通过依次刺激和抑制骨代谢来实现正性骨平衡。治疗包括六个为期14天的疗程,每天使用400单位(1 - 38)的人甲状旁腺激素(hPTH),此外,从甲状旁腺激素治疗的第2周开始,每天每千克体重使用5毫克依替膦酸二钠(EHDP),共2周。最初的治疗疗程就已导致骨代谢降低得到刺激,这可通过钙 - 47积聚率的增加得到证实(6例患者)。可以观察到碱性磷酸酶升高(4例患者);然而,这与钙的积聚并无关联。尽管如此,在此期间8例患者中只有4例实现了正性钙平衡,而碱性磷酸酶和动力学均无法预测这种效果。平衡的变化与净钙吸收的同等变化相一致。治疗阶段尿钙排泄暂时增加。我们未能检测到对维生素D代谢产物的影响。组织形态计量学研究未显示六个治疗疗程后髂嵴骨量增加。尽管如此,椎体并未出现进行性变形。我们得出结论,仅在2周后,这种治疗理念就能导致骨代谢受到刺激。

相似文献

1
Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study I, osteoporosis trial Hannover.使用(1-38)人甲状旁腺激素(hPTH)和双膦酸盐依替膦酸二钠(EHDP)对骨质疏松症低骨代谢进行刺激疗法的结果。研究I方案,汉诺威骨质疏松症试验
Klin Wochenschr. 1988 Oct 3;66(19):976-84. doi: 10.1007/BF01738113.
2
[Morphologic study of iliac crest spongiosa in patients with osteoporosis treated according to the ADFR (activation, depression of resorption, formation, repeat the cycle) with parathyroid hormone and diphosphonates (Hannover PTH I study)].[采用甲状旁腺激素和双膦酸盐,根据ADFR(激活、抑制吸收、形成、重复循环)方案治疗骨质疏松症患者的髂嵴松质骨形态学研究(汉诺威甲状旁腺激素I研究)]
Z Orthop Ihre Grenzgeb. 1990 Jan-Feb;128(1):1-5. doi: 10.1055/s-2008-1039852.
3
Morphological analysis of iliac crest bone biopsies in patients with osteoporosis and treatment according to the ADFR concept with (1-38)hPTH and diphosphonate (EHDP)--Osteoporosis Study I, Hannover.骨质疏松症患者髂嵴骨活检的形态学分析以及根据ADFR概念采用(1-38)人甲状旁腺激素和二膦酸盐(依替膦酸二钠)进行治疗——汉诺威骨质疏松症研究I
Klin Wochenschr. 1989 May 15;67(10):556. doi: 10.1007/BF01719784.
4
Calcium-47 kinetic measurements of bone turnover compared to bone histomorphometry in osteoporosis: the influence of human parathyroid fragment (hPTH 1-34) therapy.
Metab Bone Dis Relat Res. 1981;3(1):23-30. doi: 10.1016/s0221-8747(81)80019-7.
5
Short-term effects of synthetic human parathyroid hormone-(1--34) administration on bone mineral metabolism in osteoporotic patients.合成人甲状旁腺激素-(1-34)给药对骨质疏松症患者骨矿物质代谢的短期影响。
J Clin Invest. 1981 Nov;68(5):1261-71. doi: 10.1172/jci110372.
6
Bone remodeling and calcium metabolism: a correlated histomorphometric, calcium kinetic, and biochemical study in patients with osteoporosis and Paget's Disease.骨重塑与钙代谢:骨质疏松症和佩吉特病患者的组织形态计量学、钙动力学及生化相关性研究
Metabolism. 1977 Jun;26(6):589-606. doi: 10.1016/0026-0495(77)90081-6.
7
Human parathyroid peptide treatment of vertebral osteoporosis.人甲状旁腺肽治疗椎体骨质疏松症。
Osteoporos Int. 1993;3 Suppl 1:199-203. doi: 10.1007/BF01621906.
8
A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.一项随机对照试验,比较周期性甲状旁腺激素与周期性甲状旁腺激素联合序贯降钙素对改善绝经后骨质疏松症女性骨量的疗效。
J Clin Endocrinol Metab. 1997 Feb;82(2):620-8. doi: 10.1210/jcem.82.2.3762.
9
Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis.人甲状旁腺激素1-34的周期性疗程与骨化三醇交替使用,出人意料地减少了脊柱骨质疏松症中的骨重塑。
Eur J Clin Invest. 1987 Oct;17(5):421-8. doi: 10.1111/j.1365-2362.1987.tb01137.x.
10
Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients.骨质疏松症患者对序贯给予人甲状旁腺激素(1-38)和鲑鱼降钙素的骨密度和组织形态计量学反应。
Bone Miner. 1991 Jul;14(1):67-83. doi: 10.1016/0169-6009(91)90103-7.

引用本文的文献

1
Effects of teriparatide retreatment in osteoporotic men and women.特立帕肽再治疗对骨质疏松男性和女性的影响。
J Clin Endocrinol Metab. 2009 Jul;94(7):2495-501. doi: 10.1210/jc.2009-0154. Epub 2009 Apr 28.
2
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.依替膦酸二钠用于绝经后妇女骨质疏松性骨折的一级和二级预防。
Cochrane Database Syst Rev. 2008 Jan 23;2008(1):CD003376. doi: 10.1002/14651858.CD003376.pub3.
3
The role of bisphosphonates in the prevention and treatment of osteoporosis.

本文引用的文献

1
The accumulation, interpretation, and presentation of data pertaining to metabolic balances, notably those of calcium, phosphorus, and nitrogen.与代谢平衡相关的数据的积累、解读和呈现,尤其是钙、磷和氮的代谢平衡数据。
J Clin Endocrinol Metab. 1945;5:367-95. doi: 10.1210/jcem-5-9-367.
2
Homologous radioimmunoassay for human mid-regional parathyroid hormone.
J Endocrinol Invest. 1981 Jul-Sep;4(3):363-6. doi: 10.1007/BF03349458.
3
Short-term effects of synthetic human parathyroid hormone-(1--34) administration on bone mineral metabolism in osteoporotic patients.合成人甲状旁腺激素-(1-34)给药对骨质疏松症患者骨矿物质代谢的短期影响。
双膦酸盐在骨质疏松症预防和治疗中的作用。
Clin Rheumatol. 1995 Sep;14 Suppl 3:22-5. doi: 10.1007/BF02210684.
4
New bisphosphonates in osteoporosis.骨质疏松症中的新型双膦酸盐类药物。
Osteoporos Int. 1993;3 Suppl 2:S15-22. doi: 10.1007/BF01623222.
5
Bisphosphonates and osteoporosis.
Osteoporos Int. 1993;3 Suppl 1:223-5. doi: 10.1007/BF01621913.
6
Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients.在骨质疏松症患者中,采用脉冲式1-38hPTH联合治疗并序贯添加降钙素鼻喷雾剂增加椎体密度。
Calcif Tissue Int. 1989 Mar;44(3):176-80. doi: 10.1007/BF02556561.
7
Toward a cure for osteoporosis: reversal of excessive bone fragility.
Osteoporos Int. 1991 Oct;2(1):12-9. doi: 10.1007/BF01627073.
J Clin Invest. 1981 Nov;68(5):1261-71. doi: 10.1172/jci110372.
4
Assessment of 25-hydroxyvitamin D 1 alpha-hydroxylase reserve in postmenopausal osteoporosis by administration of parathyroid extract.通过给予甲状旁腺提取物评估绝经后骨质疏松症患者25-羟维生素D 1α-羟化酶储备。
J Clin Endocrinol Metab. 1981 Oct;53(4):833-5. doi: 10.1210/jcem-53-4-833.
5
Calcium-47 kinetic measurements of bone turnover compared to bone histomorphometry in osteoporosis: the influence of human parathyroid fragment (hPTH 1-34) therapy.
Metab Bone Dis Relat Res. 1981;3(1):23-30. doi: 10.1016/s0221-8747(81)80019-7.
6
Pathological and therapeutic implications of the cellular and humoral responses to parathyrin.对甲状旁腺素的细胞和体液反应的病理及治疗意义
Biochem Soc Trans. 1981 Oct;9(5):383-6. doi: 10.1042/bst0090383.
7
Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.人甲状旁腺激素片段对绝经后骨质疏松症小梁骨的合成代谢作用:一项多中心试验。
Br Med J. 1980 Jun 7;280(6228):1340-4. doi: 10.1136/bmj.280.6228.1340.
8
Protein binding assays for 25-hydroxy, 24,25-dihydroxy and 1,25-dihydroxy metabolites of vitamin D1) in human plasma.
J Clin Chem Clin Biochem. 1981 Oct;19(10):1043-50. doi: 10.1515/cclm.1981.19.10.1043.
9
Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients.老年骨质疏松患者1,25-二羟维生素D生成不足。
N Engl J Med. 1981 Aug 13;305(7):372-4. doi: 10.1056/NEJM198108133050704.
10
Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone.
Metab Bone Dis Relat Res. 1984;5(4):177-81. doi: 10.1016/0221-8747(84)90026-2.